Patents Assigned to Genentech
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20240180901
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: December 8, 2023
    Publication date: June 6, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak SAMPATH, Christian KLEIN, Wayne John FAIRBROTHER
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11999791
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: May 1, 2023
    Date of Patent: June 4, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Synthesis of a bis-mesylate salt of 4-amino-N-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide and intermediates thereto
    Patent number: 11999749
    Abstract: A manufacturing process to a bis-mesylate salt 1b of the pan-RAF inhibitor 4-amino-n-(1-((3-chloro-2-fluorophenyl)amino)-6-methylisoquinolin-5-yl)thieno[3,2-d]pyrimidine-7-carboxamide. The process features a number of efficient key reactions, including a robust and scalable Pd-catalyzed carbonylation reaction to generate thienopyrimidine 2 and a highly chemoselective Pt/V/C-catalyzed nitro group reduction to access penultimate intermediate 7. The final amide coupling of 7 and 2 was accomplished by a mild and safe protocol employing N,N,N?,N?-tetramethylchloroformamidinium hexafluorophosphate (TCFH) as the coupling reagent, to produce a 1:1 adduct of the freebase and THF. The adduct afforded compound 1b with excellent yield, purity, and form stability on a multikilogram production scale after reaction with MsOH and recrystallization. The methods are able to produce a compound having upwards of 95% purity.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: June 4, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Francis Gosselin, Stefan G. Koenig, Eduardo V. Mercado-Marin, Andreas Stumpf, Daniel Zell, Haiming Zhang, Stephan Bachmann, Diane E. Carrera, Michael E. Dalziel, Yonghui Ge, Jie Zhang, Raphael Bigler, Laure Elizabeth Simone Finet, Regis Jean Georges Mondiere, Yuki Nakagawa
  • Tie2-binding agents and methods of use
    Patent number: 11999787
    Abstract: The invention provides Tie-2 antibodies and fragments thereof and conjugates and methods of using the same.
    Type: Grant
    Filed: March 22, 2021
    Date of Patent: June 4, 2024
    Assignee: Genentech, Inc.
    Inventors: Minhong Yan, Gu Zhang, Nicholas John Agard, Danielle Marie Dicara, Philip E. Hass, Julie Q. Hang, Erin L. Christensen, Robert Paul Morse, Sarah Sanowar, Vittal Shivva
  • PROCESSES FOR SYNTHESIS OF SUBSTITUTED INDOLE INTERMEDIATES FOR THE SYNTHESIS OF SERD COMPOUNDS
    Publication number: 20240174678
    Abstract: Provided herein are processes for the preparation of compounds useful in the treatment of cancer.
    Type: Application
    Filed: December 5, 2023
    Publication date: May 30, 2024
    Applicants: Hoffmann-La Roche Inc., Genentech, Inc.
    Inventors: HAIMING ZHANG, JIE XU, GEORG WUITSCHIK, REMY ANGELAUD, SEBASTIAN HEROLD, ALFRED STUTZ, TOBIAS BRUETSCH, JOHANNES BURKHARD
  • 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS
    Publication number: 20240174696
    Abstract: Disclosed are 2,8-diazaspiro[4.5]decane compounds, including (pyrido[3,4-d]pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane compounds, (2,6-naphthyridin-1-yl)-2,8-diazaspiro[4.5]decane compounds, and (1,7-naphthyridin-4-yl)-2,8-diazaspiro[4.5]decane compounds, that are inhibitors of LATS1/2, compositions containing these compounds, and methods for inhibiting LATS1/2 activity.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 30, 2024
    Applicant: Genentech, Inc.
    Inventors: Steven John MCKERRALL, Alice Rose WONG, James John CRAWFORD, Wendy LEE, Kwong Wah LAI, Guillaume PELLETIER, Stéphanie ROY, Dana Krystin WINTER, Mikiko OKUMURA, Ruth Dorel
  • TREATMENT OF BREAST CANCER USING COMBINATION THERAPIES COMPRISING GDC-9545 AND A CDK4/6 INHIBITOR
    Publication number: 20240173306
    Abstract: Provided herein are combination therapies comprising GDC-9545 and a CDK4/6 inhibitor for treating locally advanced breast cancer or metastatic breast cancer.
    Type: Application
    Filed: January 26, 2024
    Publication date: May 30, 2024
    Applicant: Genentech, Inc.
    Inventors: Jennifer O'Hara LAUCHLE, Sandra MILAN, Melanie Carol SMITT, Marjorie C. GREEN
  • METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
    Publication number: 20240173325
    Abstract: Provided are methods for the treatment of spinal muscular atrophy (SMA) in a fetal subject in need thereof comprising administering an amount of risdiplam to a carrier of the fetal subject. Administering the amount of risdiplam to the carrier of the fetal subject results in transplacental delivery to the fetal subject, resulting in an increase in SMN protein production.
    Type: Application
    Filed: October 13, 2023
    Publication date: May 30, 2024
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Richard S. Finkel, Heidemarie Kletzl, Lutz Mueller, Renata Siciliani Scalco, Gaurav Seth, Alexander Herbert Stephan
  • Adjuvant treatment of HER2-positive breast cancer
    Patent number: 11992529
    Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: May 28, 2024
    Assignees: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Mark C. Benyunes, Graham Alexander Ross
  • Therapeutic compounds
    Patent number: 11993599
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: May 28, 2024
    Assignee: GENENTECH, INC.
    Inventors: Elisia Villemure, Joachim Rudolph, Mingshuo Zeng
  • PROCESS FOR THE PREPARATION OF BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS
    Publication number: 20240166595
    Abstract: Methods of making benzoxazepin oxazolidinone compounds as well as synthetic intermediates are described, including compound (10-2) and compound 18:
    Type: Application
    Filed: November 27, 2023
    Publication date: May 23, 2024
    Applicant: Genentech, Inc.
    Inventors: Rémy Angelaud, Tobias Bruetsch, Francis Gosselin, Chong Han, Alfred Stutz
  • IDENTIFICATION AND QUANTITATION OF RESIDUAL HOST CELL PROTEINS IN PROTEIN SAMPLES
    Publication number: 20240168036
    Abstract: The present disclosure relates to highly sensitive methods for determining the identity and quantity of one or more proteins in a sample. For example, the present disclosure provides methods for the highly sensitive identification and quantitation of residual host cell proteins in protein samples and can be adapted to identify and quantify proteins in either a targeted or a target-agnostic manner and can be modified to achieve a range of sensitivities appropriate for distinct use cases.
    Type: Application
    Filed: December 1, 2023
    Publication date: May 23, 2024
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Jia Guo, Regina Kufer, Delia Li, Feng Yang, Inn Huam Yuk, Jinhua Zhang, Lance J. Cadang, Lu Dai
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11987637
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 11, 2024
    Date of Patent: May 21, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • Prevention of disulfide bond reduction during recombinant production of polypeptides
    Patent number: 11987638
    Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Grant
    Filed: January 11, 2024
    Date of Patent: May 21, 2024
    Assignee: Genentech, Inc.
    Inventors: Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
  • FC Variants and Methods for Their Production
    Publication number: 20240158513
    Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 16, 2024
    Applicant: Genentech, Inc.
    Inventors: J. Michael ELLIOTT, Justin M. Scheer
  • HARVEST OPERATIONS FOR RECOMBINANT PROTEINS
    Publication number: 20240158825
    Abstract: The present invention contemplates a method of producing a recombinant protein comprising (a) fermenting a prokaryotic host cell wherein said prokaryotic host cell has been transformed with a nucleic acid encoding said recombinant protein, and (b) harvesting said recombinant protein under conditions where dO2 levels are greater than 0%, and (c) purifying said recombinant protein to a filtered bulk, wherein said filtered bulk does not contain detectable DHNA-recombinant protein adduct, as measured by an IEC assay at 310 nm.
    Type: Application
    Filed: January 22, 2024
    Publication date: May 16, 2024
    Applicant: Genentech, Inc.
    Inventors: Michael W. LAIRD, Richard ST. JOHN, Jane V. GUNSON, Kimberly KALEAS, Deepa NADARAJAH, Rachel L.E. ADAMS, Bradley R. SNEDECOR
  • METHODS OF MAKING FUCOSYLATED AND AFUCOSYLATED FORMS OF A PROTEIN
    Publication number: 20240158536
    Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.
    Type: Application
    Filed: September 25, 2023
    Publication date: May 16, 2024
    Applicant: Genentech, Inc.
    Inventors: Shahram MISAGHI, John B. LOWE, Bradley Richard SNEDECOR
  • PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES
    Publication number: 20240158527
    Abstract: The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
    Type: Application
    Filed: January 11, 2024
    Publication date: May 16, 2024
    Applicant: Genentech, Inc.
    Inventors: Yung-Hsiang KAO, Michael W. LAIRD, Melody Trexler SCHMIDT, Rita L. WONG, Daniel P. HEWITT
  • ANTI-KLK7 ANTIBODIES, ANTI-KLK5 ANTIBODIES, MULTISPECIFIC ANTI-KLK5/KLK7 ANTIBODIES, AND METHODS OF USE
    Publication number: 20240150491
    Abstract: The invention provides anti-KLK7 antibodies, anti-KLK5 antibodies, anti-KLK5/KLK7 multispecific antibodies, and methods of using the same.
    Type: Application
    Filed: December 19, 2023
    Publication date: May 9, 2024
    Applicant: Genentech, Inc.
    Inventors: James Thomas KOERBER, Wyne Pun LEE, Tangsheng YI, Juan ZHANG, Cary Dean AUSTIN, Cecilia P.C. CHIU, Joseph Edward CHAVARRIA-SMITH, Jawahar SUDHAMSU
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20240150364
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: November 13, 2023
    Publication date: May 9, 2024
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley